Altrenogest

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Altrenogest
DrugBank Accession Number
DB11372
Background

Altrenogest, also known as allyltrenbolone, is a steroidal progestin that is widely used in veterinary medicine to suppress estrus in animals.

Type
Small Molecule
Groups
Vet approved
Structure
Weight
Average: 310.437
Monoisotopic: 310.193280077
Chemical Formula
C21H26O2
Synonyms
  • 17-alpha-Allyl-estratriene-4,9,11,17-beta-ol-3-one
  • Allyl trenbolone
  • Allyltrenbolone
  • Altrenogest
  • Altrenogestum
External IDs
  • A-35957
  • DRC 6246
  • R 2267
  • RU 2267
  • RU-2267

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabAltrenogest may decrease the anticoagulant activities of Abciximab.
AcenocoumarolAltrenogest may decrease the anticoagulant activities of Acenocoumarol.
AlteplaseAltrenogest may decrease the anticoagulant activities of Alteplase.
AncrodAltrenogest may decrease the anticoagulant activities of Ancrod.
AnistreplaseAltrenogest may decrease the anticoagulant activities of Anistreplase.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Estrane steroids
Direct Parent
Estrogens and derivatives
Alternative Parents
3-oxosteroids / 17-hydroxysteroids / Cyclohexenones / Tertiary alcohols / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
17-hydroxysteroid / 3-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Carbonyl group / Cyclic alcohol / Cyclic ketone / Cyclohexenone / Estrogen-skeleton / Hydrocarbon derivative
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
2U0X0JA2NB
CAS number
850-52-2
InChI Key
VWAUPFMBXBWEQY-ANULTFPQSA-N
InChI
InChI=1S/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,13,18-19,23H,1,4-7,9-10,12H2,2H3/t18-,19+,20+,21+/m1/s1
IUPAC Name
(1R,3aS,3bS,11aS)-1-hydroxy-11a-methyl-1-(prop-2-en-1-yl)-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,11aH-cyclopenta[a]phenanthren-7-one
SMILES
[H][C@@]12CC[C@@](O)(CC=C)[C@@]1(C)C=CC1=C3CCC(=O)C=C3CC[C@@]21[H]

References

General References
  1. Machnik M, Hegger I, Kietzmann M, Thevis M, Guddat S, Schanzer W: Pharmacokinetics of altrenogest in horses. J Vet Pharmacol Ther. 2007 Feb;30(1):86-90. [Article]
  2. Kornheiser KM: Use of altrenogest in mares. J Am Vet Med Assoc. 1989 May 1;194(9):1150. [Article]
  3. Hodgson D, Howe S, Jeffcott L, Reid S, Mellor D, Higgins A: Effect of prolonged use of altrenogest on behaviour in mares. Vet J. 2005 May;169(3):322-5. [Article]
  4. Webel SK, Squires EL: Control of the oestrous cycle in mares with altrenogest. J Reprod Fertil Suppl. 1982;32:193-8. [Article]
  5. Soede NM, Bouwman EG, Langendijk P, van der Laan I, Kanora A, Kemp B: Follicle development during luteal phase and altrenogest treatment in pigs. Reprod Domest Anim. 2007 Jun;42(3):329-32. [Article]
  6. Sigler DH, Ericson DE, Gibbs PG, Kiracofe GH, Stevenson JS: Reproductive traits, lactation and foal growth in mares fed altrenogest. J Anim Sci. 1989 May;67(5):1154-9. [Article]
  7. Stevenson JS, Davis DL, Pollmann DS: Altrenogest and fat for summer breeding of primiparous sows. J Anim Sci. 1985 Aug;61(2):480-6. [Article]
  8. dos Santos JM, Wentz I, Bortolozzo FP, Barioni W Jr: Early-weaned sows: altrenogest therapy, estrus, ovulation, and reproductive performance. Anim Reprod Sci. 2004 Sep;84(3-4):407-13. [Article]
  9. Davis DL, Stevenson JS, Schmidt WE: Scheduled breeding of gilts after estrous synchronization with altrenogest. J Anim Sci. 1985 Mar;60(3):599-602. [Article]
  10. Rhodes MT, Davis DL, Stevenson JS: Flushing and altrenogest affect litter traits in gilts. J Anim Sci. 1991 Jan;69(1):34-40. [Article]
KEGG Drug
D02840
ChemSpider
8216634
RxNav
1314612
ChEMBL
CHEMBL1315492
ZINC
ZINC000004214784
Wikipedia
Altrenogest

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0301 mg/mLALOGPS
logP3.74ALOGPS
logP3.2Chemaxon
logS-4ALOGPS
pKa (Strongest Acidic)18.4Chemaxon
pKa (Strongest Basic)-0.18Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area37.3 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity95.46 m3·mol-1Chemaxon
Polarizability36.06 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0097000000-b2fda083f74e5d5a100f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0009000000-d0d540592a615326d841
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0069000000-bada304e4fa6eeb0fbe8
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-02dj-0190000000-173a622ee96a3405e32d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0aor-0293000000-6ebdab6da00b9f6ae007
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-060a-0920000000-9d1947f5408526d36ea3
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-187.6579663
predicted
DarkChem Lite v0.1.0
[M-H]-175.27608
predicted
DeepCCS 1.0 (2019)
[M+H]+187.8354663
predicted
DarkChem Lite v0.1.0
[M+H]+177.65073
predicted
DeepCCS 1.0 (2019)
[M+Na]+187.5999663
predicted
DarkChem Lite v0.1.0
[M+Na]+184.56354
predicted
DeepCCS 1.0 (2019)

Drug created at February 25, 2016 18:13 / Updated at February 21, 2021 18:53